Drug Trial Radar · NCT04261712
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
43
Actual
Start
Jan 29, 2020
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Crinetics Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 10, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.
Conditions
- Acromegaly
Interventions
PaltusotineDrug
Paltusotine, once daily by mouth
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) throughout the studyTime frame: Week 316
Locations
22 sites in 7 countries. Site status is shown where the registry gives one.
Crinetics Study Site
Los Angeles, California
Crinetics Study Site
Chicago, Illinois
Crinetics Study Site
Boston, Massachusetts
Crinetics Study Site
Columbus, Ohio
Crinetics Study Site
Pittsburgh, Pennsylvania
Crinetics Study Site
Pittsburgh, Pennsylvania
Crinetics Study Site
Dallas, Texas
Crinetics Study Site
Rio de Janeiro, Brazil
Crinetics Study Site
Rio de Janeiro, Brazil
Crinetics Study Site
São Paulo, Brazil
Crinetics Study Site
Curitiba, Paraná, Brazil
Crinetics Study Site
München, Germany
Crinetics Study Site
Athens, Greece
Crinetics Study Site 1
Athens, Greece
Crinetics Study Site 2
Athens, Greece
Crinetics Study Site
Thessaloniki, Greece
Crinetics Study Site
Budapest, Hungary
Crinetics Study Site
Budapest, Hungary
Crinetics Study Site
Pécs, Hungary
Crinetics Study Site
Belgrade, Serbia
Crinetics Study Site
Coventry, United Kingdom
Crinetics Study Site
Leeds, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.